[HTML][HTML] Pertuzumab plus trastuzumab plus docetaxel for metastatic breast cancer

J Baselga, J Cortés, SB Kim, SA Im… - … England Journal of …, 2012 - Mass Medical Soc
Background The anti–human epidermal growth factor receptor 2 (HER2) humanized monoclonal
antibody trastuzumab improves the outcome in patients with HER2-positive metastatic …

[HTML][HTML] Use of chemotherapy plus a monoclonal antibody against HER2 for metastatic breast cancer that overexpresses HER2

…, J Wolter, M Pegram, J Baselga… - New England journal …, 2001 - Mass Medical Soc
Background The HER2 gene, which encodes the growth factor receptor HER2, is amplified
and HER2 is overexpressed in 25 to 30 percent of breast cancers, increasing the …

[HTML][HTML] Everolimus in postmenopausal hormone-receptor–positive advanced breast cancer

J Baselga, M Campone, M Piccart… - … England Journal of …, 2012 - Mass Medical Soc
Background Resistance to endocrine therapy in breast cancer is associated with activation of
the mammalian target of rapamycin (mTOR) intracellular signaling pathway. In early studies…

A view on drug resistance in cancer

N Vasan, J Baselga, DM Hyman - Nature, 2019 - nature.com
The problem of resistance to therapy in cancer is multifaceted. Here we take a reductionist
approach to define and separate the key determinants of drug resistance, which include …

[HTML][HTML] Phase II trial of pertuzumab and trastuzumab in patients with human epidermal growth factor receptor 2–positive metastatic breast cancer that progressed …

J Baselga, KA Gelmon, S Verma… - Journal of clinical …, 2010 - ncbi.nlm.nih.gov
Purpose Pertuzumab, a human epidermal growth factor receptor 2 (HER2)–targeted monoclonal
antibody, potently inhibits HER2 dimerization and HER-mediated signaling pathways. …

Epidermal growth factor receptor mutations and gene amplification in non–small-cell lung cancer: Molecular analysis of the IDEAL/INTACT gefitinib trials

…, M Fukuoka, MG Kris, J Baselga… - Journal of Clinical …, 2005 - ascopubs.org
Purpose Most cases of non–small-cell lung cancer (NSCLC) with dramatic responses to
gefitinib have specific activating mutations in the epidermal growth factor receptor (EGFR), but …

BIM expression in treatment-naive cancers predicts responsiveness to kinase inhibitors

…, EJ Coffman, CH Benes, HL Gómez, J Baselga… - Cancer discovery, 2011 - AACR
Cancers with specific genetic mutations are susceptible to selective kinase inhibitors.
However, there is a wide spectrum of benefit among cancers harboring the same sensitizing …

The landscape of somatic copy-number alteration across human cancers

…, JE Tepper, JA Fletcher, J Tabernero, J Baselga… - Nature, 2010 - nature.com
A powerful way to discover key genes with causal roles in oncogenesis is to identify
genomic regions that undergo frequent alteration in human cancers. Here we present high-…

Lapatinib with trastuzumab for HER2-positive early breast cancer (NeoALTTO): a randomised, open-label, multicentre, phase 3 trial

J Baselga, I Bradbury, H Eidtmann, S Di Cosimo… - The Lancet, 2012 - thelancet.com
Background The anti-HER2 monoclonal antibody trastuzumab and the tyrosine kinase inhibitor
lapatinib have complementary mechanisms of action and synergistic antitumour activity …

ESR1 ligand-binding domain mutations in hormone-resistant breast cancer

…, G Hortobagyi, G Greene, M Berger, J Baselga… - Nature …, 2013 - nature.com
Seventy percent of breast cancers express estrogen receptor (ER), and most of these are
sensitive to ER inhibition. However, many such tumors for unknown reasons become refractory …